False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance

被引:68
作者
Quon J.S. [1 ]
Moosavi B. [1 ]
Khanna M. [2 ]
Flood T.A. [3 ]
Lim C.S. [1 ]
Schieda N. [1 ]
机构
[1] Department of Medical Imaging, The Ottawa Hospital, The University of Ottawa, 1053 Carling Avenue, Ottawa, K1Y 4E9, ON
[2] Department of Radiology, Hamad General Hospital, Doha
[3] Department of Pathology, The Ottawa Hospital, The University of Ottawa, 501 Smyth Road, Ottawa, K1H 8 L6, ON
关键词
Active surveillance of prostate cancer; Diffusion-weighted imaging; Multi-parametric MRI; Prostate cancer; Targeted biopsy;
D O I
10.1007/s13244-015-0411-3
中图分类号
学科分类号
摘要
Abstract: MP-MRI is a critical component in active surveillance (AS) of prostate cancer (PCa) because of a high negative predictive value for clinically significant tumours. This review illustrates pitfalls of MP-MRI and how to recognise and avoid them. The anterior fibromuscular stroma and central zone are low signal on T2W-MRI/apparent diffusion coefficient (ADC), resembling PCa. Location, progressive enhancement and low signal on b ≥1000 mm²/s echo-planar images (EPI) are differentiating features. BPH can mimic PCa. Glandular BPH shows increased T2W/ADC signal, cystic change and progressive enhancement; however, stromal BPH resembles transition zone (TZ) PCa. A rounded morphology, low T2 signal capsule and posterior/superior location favour stromal BPH. Acute/chronic prostatitis mimics PCa at MP-MRI, with differentiation mainly on clinical grounds. Visual analysis of diffusion-weighted MRI must include EPI and appropriate windowing of ADC. Quantitative ADC analysis is limited by lack of standardization; the ADC ratio and ADC histogram analysis are alternatives to mean values. DCE lacks standardisation and has limited utility in the TZ, where T2W/DWI are favoured. Targeted TRUS-guided biopsies of MR-detected lesions are challenging. Lesions detected on MP-MRI may not be perfectly targeted with TRUS and this must be considered when faced with a suspicious lesion on MP-MRI and a negative targeted TRUS biopsy histopathological result. Keypoints: • Multi-parametric MRI plays a critical role in prostate cancer active surveillance. • Low T2W signal intensity structures appear dark on ADC, potentially simulating cancer. • Stromal BPH mimics cancer at DWI and DCE. • Long b value trace EPI should be reviewed • Targeted biopsy of MR-detected lesions using TRUS guidance may be challenging. © 2015, The Author(s).
引用
收藏
页码:449 / 463
页数:14
相关论文
共 70 条
  • [1] Guidelines on prostate cancer, Arnhem, (2012)
  • [2] Thomsen F.B., Brasso K., Klotz L.H., Roder M.A., Berg K.D., Iversen P., Active surveillance for clinically localized prostate cancer–a systematic review, J Surg Oncol, 109, pp. 830-835, (2014)
  • [3] Heidenreich A., Bellmunt J., Bolla M., Et al., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol, 59, pp. 61-71, (2011)
  • [4] Rothwax J.T., George A.K., Wood B.J., Pinto P.A., Multiparametric MRI in biopsy guidance for prostate cancer: fusion-guided, Biomed Res Int, 2014, (2014)
  • [5] Eskew L.A., Bare R.L., McCullough D.L., Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate, J Urol, 157, pp. 199-202, (1997)
  • [6] Presti J.C., O'Dowd G.J., Miller M.C., Mattu R., Veltri R.W., Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study, J Urol, 169, pp. 125-129, (2003)
  • [7] Babaian R.J., Toi A., Kamoi K., Et al., A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy, J Urol, 163, pp. 152-157, (2000)
  • [8] Noguchi M., Stamey T.A., McNeal J.E., Yemoto C.M., Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer, J Urol, 166, pp. 104-109, (2001)
  • [9] Bott S.R., Young M.P., Kellett M.J., Parkinson M.C., Anterior prostate cancer: is it more difficult to diagnose?, BJU Int, 89, pp. 886-889, (2002)
  • [10] Eberhardt S.C., Carter S., Casalino D.D., Et al., ACR appropriateness criteria prostate cancer–pretreatment detection, staging, and surveillance, J Am Coll Radiol, 10, pp. 83-92, (2013)